© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jan 16, 2015, the consensus forecast amongst 7 polled investment analysts covering CTI BioPharma Corp advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in CTI BioPharma Corp.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 6 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 5.25, with a high estimate of 6.50 and a low estimate of 3.00. The median estimate represents a 139.73% increase from the last price of 2.19. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On Oct 29, 2014, CTI BioPharma Corp reported 3rd quarter 2014 earnings of 0.03 per share. This result exceeded the -0.03 consensus loss of the 5 analysts covering the company and outperformed last year's 3rd quarter results by 0.23.
The next earnings announcement is expected on Mar 02, 2015. View Full Interim Financials
|Average growth rate||+5.00%|
CTI BioPharma Corp reported annual 2013 losses of -0.43 per share on Mar 04, 2014.
The next earnings announcement from CTI BioPharma Corp is expected the week of Mar 02, 2015. View Full Annual Financials
|Average growth rate||+45.22%|
CTI BioPharma Corp. had 3rd quarter 2014 revenues of 39.5340m. This bettered the 24.9993m consensus of the 4 analysts covering the company. This was 2,843.71% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+763.47%|
CTI BioPharma Corp. had revenues for the full year 2013 of 2.3140m. View Full Annual Financials
|Average growth rate||+66.25%|